US5158934A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inducing bone growth using TGF-β
Assignee: Genentech Inc
•
Filing: 1989-09-01
•
Granted: 1992-10-27
•
Expires: 2009-09-01
Abstract
Abstract A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-β in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-β and a source of osteogenic cells in a pharmaceutically acceptable carrier.
Inventors
- 👤 Arthur J. Ammann
- 👤 Christopher G Rudman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:56
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61F2002/2817; A61F2/30; A61F2002/30001; A61F2002/30667; A61F2002/30677; A61L2430/00; A61L2430/02
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
80 words
A method for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the site in the presence of an osteogenic cell source, an effective amount of a composition consisting essentially of TGF-β in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered to the animal in an amount effective to induce growth of morphologically normal, mature bone at the site.
Claim 2
Independent Claim
80 words
A method for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the site in the presence of an osteogenic cell source, an effective amount of a composition consisting essentially of TGF-β in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered to the animal in an amount effective to induce growth of morphologically normal, mature bone at the site.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the TGF-β is TGF-β1, TGF-β2, TGF-β3, TGF-β4, TGF-β5, or latent TGF-β.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the TGF-β is TGF-β1.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein if the site is a periodontal site, the osteogenic cell source is an exogenous source.
Claim 6
Dependent Claim
31 words
The method of claim 1 wherein the excluded bone morphogenetic cofactor is one derived from a bovine bone source and has a molecular weight of about 28 Kd or 36 Kd.
Claim 7
Dependent Claim
24 words
The method of claim 1 wherein the skeletal tissue is deficient as a result of surgical intervention, removal of tumor, ulceration, implant, or fracture.
Claim 8
Dependent Claim
22 words
The method of claim 1 wherein the osteogenic cell source is dispersed whole bone marrow cells, perichondrium, periosteum, or a cell line.
Claim 9
Dependent Claim
16 words
The method of claim 7 wherein the osteogenic cell source is naturally present at the site.
Claim 10
Dependent Claim
16 words
The method of claim 7 wherein the osteogenic cell source is present in the TGF-β composition.
Claim 11
Dependent Claim
11 words
The method of claim 1 wherein the carrier is a polysaccharide.
Claim 12
Dependent Claim
17 words
The method of claim 1 wherein the composition allows for sustained release of TGF-β at the site.
Claim 13
Dependent Claim
11 words
The method of claim 1 wherein the animal is a human.
References Cited (Backward Citations)
US4642120A
Cited
US4774322A
Cited
US4774228A
Cited
US4810691A
Cited
US4843063A
Cited
US4563350A
Cited
US4919939A
Cited
US4702734A
Cited
EP0268561A2
Cited
US4863732A
Cited
US4968590A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-27 | 1996-04-27 | 1996-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-27 | 2000-04-27 | 2000-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-27 | 2004-04-27 | 2004-10-27 | $7700.00 | Window Closed / Lapsed |